Reporter Immune Cells for In Vivo CAR T Cell Tracking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR T cell therapy faces challenges in effectively targeting solid tumors due to resistance mechanisms and impaired persistence at tumor sites, necessitating a method to track and monitor CAR T cells within the body for improved treatment efficacy.
Innovation Solution
Development of specialized reporter immune cells using non-endogenous expression vectors and biotinylated DOTA-based haptens with radionuclide-labeled DOTA-bearing bischelates for real-time tracking and monitoring of CAR T cells' biodistribution, viability, and expansion through PET/SPECT imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR T cell therapy is administered to treat solid tumors, then the therapy may target blood and lymph node tumors effectively, but it fails to effectively target solid tumors due to resistance mechanisms and impaired persistence
Solution Approach 1:
The patent introduces a tracking system using reporter genes (e.g., luciferase) and imaging technologies (bioluminescence imaging, PET/SPECT) that provide real-time feedback on CAR T cell biodistribution, viability, and expansion. This feedback mechanism allows clinicians to monitor whether CAR T cells are reaching tumor sites and persisting adequately, enabling assessment of therapy effectiveness and identification of resistance mechanisms in solid tumors.
2Ease of operation
If CAR T cells are administered to patients, then immune surveillance and attack may occur, but the CAR T cells do not find their way to the tumor due to resistance mechanisms in the tumor microenvironment
Solution Approach 1:
The tracking system provides continuous feedback on CAR T cell location and distribution within the body through imaging modalities. Reporter genes expressed by CAR T cells enable detection via bioluminescence imaging, PET, or SPECT, revealing whether cells are navigating to tumor sites or being deflected by the tumor microenvironment.
Solution Approach 2:
The patent employs reporter genes that produce detectable signals analogous to color changes in optical imaging. For example, luciferase expression produces bioluminescence that can be visualized, and radionuclide labeling enables detection through PET/SPECT imaging, allowing visualization of CAR T cell distribution and tumor targeting.
3Duration of action of moving object
If CAR T cells are administered for therapy, then treatment may be provided, but long-term persistence of CAR T cells at the tumor site is impaired
Solution Approach 1:
The tracking system enables longitudinal monitoring of CAR T cell persistence at tumor sites through repeated imaging studies. By tracking reporter gene expression and radionuclide signal over time, clinicians can assess whether CAR T cells are maintaining presence at tumor sites or declining, providing critical information about long-term retention and persistence.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables precise tracking and monitoring of CAR T cells, potentially enhancing their targeting and persistence at tumor sites, thereby improving the effectiveness of CAR T cell therapy for solid tumors.
Implementation Method 1
tracking and monitoring of CAR T cells' biodistribution, viability, and expansion through PET/SPECT imaging
Data Source
AI summary
The present disclosure provides kits and methods for tracking or monitoring in vivo biodistribution, viability, and/or expansion of immune cells in a cancer patient undergoing cellular immunotherapy.